1,721,091 research outputs found

    Acute profound abciximab induced thrombocytopenia: a correct management of a methodological error

    No full text
    Thrombocytopenia is a rare complication of glycoprotein IIb/IIIa treatment. We report a case of an acute profound abciximab induced thrombocytopenia and its successful management. The patient, presenting with unstable angina, underwent percutaneous coronary intervention with implantation of three drug eluting stents without receiving a clopidogrel loading dose according to guidelines. The rapid drop in the platelet count after abciximab elastomeric pump infusion was treated with drug discontinuation and platelet transfusion. The high risk of stent thrombosis was avoided by a timely readministration of the dual antiplatelet treatment

    Magnetic resonance imaging of aortic disease in the elderly.

    No full text
    The aim of this study was to compare magnetic resonance imaging (MRI) with other imaging techniques in detection of aortic disease in the elderly. Methods: Fifty-seven patients (40 men, 17 women; age range, 66 to 84 years; mean age, 73 years) were divided into two groups. Group A included 21 patients with aortic disease diagnosed by angiography who underwent MRI for comparison with ultrasonography or computed tomography (CT). Group B included 36 patients, none of whom had prior angiography, who had suspected aortic lesion because of abnormal results on clinical examination (12 patients), radiography (10 patients), ultrasonography (18 patients), or CT (14 patients). Results: In group A, the MRI results correlated with the angiographic findings in all 21 patients (100%); MRI sensitivity was calculated to be 95%. In group B, MRI was conclusive in 28 of 36 patients. Conclusions: MRI proved to be a useful noninvasive imaging tool for diagnosis and follow-up of elderly patients with aortic disease

    Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective

    Full text link
    Ischemic heart disease is the single leading cause of death and a significant cause of morbidity among women in industrialized countries. Current guidelines recommend antiplatelet therapy as the main cornerstone for the prevention and treatment of cardiovascular disease. Unfortunately, evidence is emerging that the response to antiplatelet drugs differs according to sex, although the biological basis for this gender disparity is unknown. In order to explain the epidemiological data showing a more severe clinical expression of cardiovascular disease in addition to adverse outcomes despite optimal pharmacological and interventional approaches in women compared to men, differences in platelet reactivity related to sex and gender are currently under investigation. In this report, we review available data from clinical trials of antiplatelet drugs administered for primary and secondary prevention, focusing on the underenrollment of female subjects in interventional randomized studies and weak community awareness of the impact of cardiovascular disease on life expectancy in women. Based on our findings, the development of real gender-oriented evidence-based guidelines for antiplatelet use in the setting of cardiovascular disease is urgently required
    corecore